Ongaro Marie, Mathys Philippe, Zampaglione Lucia, Negro Francesco
Service de gastroentérologie et hépatologie, HUG, 1211 Genève 14.
Service de pathologie clinique, HUG, 1211 Genève 14.
Rev Med Suisse. 2021 Sep 1;17(748):1453-1456.
Treatment of hepatitis C has known major progress thanks to direct-acting antivirals resulting in the healing, defined by a viral clearance (sustained virological response [SVR]), in the vast majority of patients. However, there is a residual risk of progressive liver damage in a minority of patients, potentially leading to complications such as liver decompensation, hepatocellular carcinoma and/or death. This article discusses the current knowledge of residual liver disease after treatment, the impact of comorbidities and the factors potentially predicting patients at risk of complications and warranting surveillance.
得益于直接作用抗病毒药物，丙型肝炎的治疗取得了重大进展，绝大多数患者实现了病毒清除（持续病毒学应答[SVR]）从而治愈。然而，少数患者仍存在肝脏进行性损伤的残余风险，可能导致诸如肝失代偿、肝细胞癌和/或死亡等并发症。本文讨论了治疗后残余肝病的现有知识、合并症的影响以及可能预测有并发症风险并需要监测的患者的因素。
